UBS Group’s The Oncology Institute Warrant TOIIW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-3,670
Closed -$187 10931
2025
Q2
$187 Buy
3,670
+649
+21% +$41 ﹤0.01% 9937
2025
Q1
$82 Sell
3,021
-85
-3% -$2 ﹤0.01% 9966
2024
Q4
$16 Sell
3,106
-2,977
-49% -$46 ﹤0.01% 9787
2024
Q3
$122 Sell
6,083
-2,706
-31% -$54 ﹤0.01% 9138
2024
Q2
$229 Buy
+8,789
New +$678 ﹤0.01% 9058
2023
Q4
Sell
-1,034
Closed -$88 9891
2023
Q3
$88 Buy
+1,034
New +$84 ﹤0.01% 8916
2023
Q1
Sell
-610
Closed -$67 10378
2022
Q4
$67 Sell
610
-4,889
-89% -$1.59K ﹤0.01% 10448
2022
Q3
$3K Buy
5,499
+25
+0.5% +$17 ﹤0.01% 9587
2022
Q2
$3K Buy
5,474
+1,000
+22% +$920 ﹤0.01% 9368
2022
Q1
$5K Buy
4,474
+102
+2% +$93 ﹤0.01% 9169
2021
Q4
$3K Buy
+4,372
New +$5.41K ﹤0.01% 9696

Other funds holding TOIIW

UBS Group's TOIIW Position: Q3 2025 in Review

UBS Group sold out of The Oncology Institute Warrant (TOIIW) in Q3 2025, closing a stake of 3,670 shares — an estimated $187 sold.

UBS Group first reported a position in TOIIW in Q4 2021 and held it in 11 quarters. The position peaked at $5K in Q1 2022. 12 funds tracked by Wall St. Rank hold TOIIW as of Q3 2025.

  • UBS Group reported no remaining The Oncology Institute Warrant position as of Q3 2025 after selling out during the quarter.
  • UBS Group sold 3,670 The Oncology Institute Warrant shares in Q3 2025, an estimated $187.
  • UBS Group first reported a position in The Oncology Institute Warrant in Q4 2021 and held it in 11 quarters.
  • UBS Group's The Oncology Institute Warrant position peaked at $5K in Q1 2022.
  • 12 funds tracked by Wall St. Rank held The Oncology Institute Warrant as of Q3 2025.

Based on UBS Group's 13F filing for Q3 2025, filed 13 Nov 2025.